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Abstract
Background: Parkinson’s Disease is a degenerative neurological condition that causes movement problems and
other distressing symptoms. People with Parkinson’s disease gradually lose their independence and strain is placed
on family members. A multidisciplinary approach to rehabilitation for people with Parkinson’s is recommended but
has not been widely researched. Studies are needed that investigate cost-effective community-based service
delivery models to reduce disability and dependency and admission to long term care, and improve quality of life.
Methods: A pragmatic three parallel group randomised controlled trial involving people with Parkinson’s Disease
and live-in carers (family friends or paid carers), and comparing: management by a specialist multidisciplinary team
for six weeks, according to a care plan agreed between the professionals and the patient and carer (Group A);
multidisciplinary team management and additional support for four months from a trained care assistant (Group B);
usual care, no coordinated team care planning or ongoing support (Group C). Follow up will be for six months to
determine the impact and relative cost-effectiveness of the two interventions, compared to usual care. The primary
outcomes are disability (patients) and strain (carers). Secondary outcomes include patient mobility, falls, speech,
pain, self efficacy, health and social care use; carer general health; patient and carer social functioning,
psychological wellbeing, health related quality of life. Semi structured interviews will be undertaken with providers
(team members, care assistants), service commissioners, and patients and carers in groups A and B, to gain
feedback about the acceptability of the interventions. A cost - effectiveness evaluation is embedded in the trial.
Discussion: The trial investigates components of recent national policy recommendations for people with long
term conditions, and Parkinson’s Disease in particular, and will provide guidance to inform local service planning
and commissioning.
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Parkinson’s disease is a degenerative neurological condi-
tion that affects mainly older people, but also significant
numbers with young onset [1]. Although designated a
movement disorder, it additionally inflicts a range of
distressing non motor symptoms. As the disease pro-
gresses, people with Parkinson’s become increasingly
dependent and a considerable burden is carried by
family carers. The mainstay of management is a phar-
macological regimen which gradually becomes less effec-
tive, and more complicated. This is supported by
rehabilitative therapies, assistive technologies and occa-
sionally surgery. A multidisciplinary team (MDT)
approach to rehabilitation is accepted best-practice
[2-4], but has not been widely researched [4-7]. Whilst a
self management programme has been found to have
positive effects on health-related quality of life at six
months [8], other community-based studies have only
measured immediate outcomes [9,10], or found no
longer term benefits [11]. A need has been expressed
for studies that identify cost-effective service delivery
models that reduce disability and dependency and pre-
vent admission to long term care [3-7].
The SPIRiTT study (Specialist Parkinson’sI n t e g r a t e d
Rehabilitation Team Trial) builds on the findings of a
previous multidisciplinary rehabilitation programme,
coordinated by a Parkinson’s Nurse Specialist (PNS) in a
day hospital setting [12]. This intervention resulted in
significant immediate gains for patients in mobility,
independence, wellbeing and health-related quality of
life [10], but, in the absence of continuing input, these
benefits had largely dissipated four months after the
intervention ended [12]. Moreover, the accompanying
economic evaluation showed that day hospital treatment
incurred facility overhead costs and involved the use of
expensive hospital transport for patients with more
advanced disease who were unable to make their own
arrangements [13]. SPIRiTT specifically addresses the
issue of patient transport raised by the day hospital
model by delivering rehabilitation to people in their
own homes. Moreover, it evaluates whether the fading
of benefit when specialist input is withdrawn, (a com-
mon feature of time limited rehabilitation interventions
[5]), can be avoided in a cost - effective way by provid-
ing continuing support from specially trained care assis-
tants. Participants in SPIRiTT will receive an equivalent
package of specialist rehabilitation to that used in the
day hospital study so that valid comparisons can be
drawn between the models of domiciliary and day hospi-
tal provision.
The SPIRiTT model of service delivery is grounded in
the recommendations of several recent policy docu-
ments of the English National Health Service (NHS).
These promote: the integration of health and social care
services [14], provision of services closer to patients’
homes [14], coordination of care for particular patient
groups by specialist disease-specific nurses [15], sup-
ported self management [15], and personalised care
planning, rehabilitation and carer support in order to
reduce costly unplanned hospital admissions [16]. More-
over, guidelines from the National Institute for Health
and Clinical Excellence (NICE) for the management of
Parkinson’s disease [3] recommend regular patient
review, comprehensive care plans, a central role for PNS
and regular access to physiotherapy, occupational ther-
apy and speech and language therapy.
Many people with Parkinson’s do not currently see
individual therapists and even fewer receive coordinated
MDT input [17,18]. SPIRiTT will investigate the cost-
effectiveness of implementing a proactive approach to
Parkinson’s management, in line with recent recommen-
dations. Other research has shown routine assessment
and support for older people living in the community
with a variety of conditions can have positive effects on
mortality and admission to long term care [19]. Evalua-
tions have been conducted in a range of countries,
including the United States [20-23], Canada [24], Austra-
lia [25,26], Denmark [27,28], Italy [29] and Switzerland
[30], but overall evidence on outcomes (such as physical
functioning and health-related quality of life), service use
and costs is inconsistent [26,31]. The findings from SPIR-
iTT will extend the current evidence base through a
focus on outcomes for people with Parkinson’s.
Capacity constraints in the form of high nurse case-
l o a d sa n ds h o r t a g e so ft h e r a p i s t sw e r ei d e n t i f i e db y
NICE as barriers to the delivery of their guidance for
management of Parkinson’s disease [3], and these have
been confirmed by a recent survey of PNS [32]. Whilst
NICE recommends a caseload of 300 patients, over half
of PNS have lists in excess of 500, with adverse effects
on the amount of routine support they can provide to
patients. In common with other advanced practice
nurses in the community, PNS report undertaking a
variety of tasks (some of which do not require advanced
skills), and that time pressures create a need to risk stra-
tify patients, and a focus on ‘crisis’ management, rather
than ongoing advice and support [33,34]. Use of care
assistants, trained in the special features and manage-
ment of Parkinson’s, working with PNS and multidisci-
plinary teams of healthcare professionals in the
community on assigned tasks appropriate to their skill
level and knowledge, is one way in which resources for
delivering care and support to people with Parkinson’s
can be increased.
Competency-based training enables non registered
staff to properly complement the activities of
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meet supervision, delegation and accountability chal-
lenges [36]. Trained care assistants have been shown to
be effective at underpinning professional working and to
have a positive impact on nurse’s ability to provide high
quality care, their work experiences, and the cost-effec-
tiveness of service delivery [37]. The use of trained assis-
tants is consistent with NHS policy for the health and
social care workforce which advocates the integration of
non registered health and social care workers with
enhanced roles in MDTs, to implement and deliver
therapy and monitor and support patients [16,38], as a
means of increasing the flexibility, efficiency and respon-
siveness of services [39,40].
The aims of the SPIRiTT study are to evaluate two
models of specialist MDT rehabilitation for people with
Parkinson’s in the community, to add to the existing evi-
dence base, to inform future service development and
commissioning, and ultimately to improve the quality of
care and outcomes for patients and family carers. The spe-
cialist intervention is based on a rehabilitation service that
works with the patient and family to resolve problems,
through a process of goal setting, care planning, interven-
tion and evaluation, to achieve outcomes that maximize
functioning and social participation with minimum dis-
tress to patient or family carer [41]. The research will
explore not just the multidisciplinary professional input,
but also budgetary and management arrangements, and
barriers and facilitators to cross sector working, that may
impact on future implementation of the model.
The specific objectives are to:
1. Implement a specialist neurological rehabilitation
service for people with Parkinson’sa n dt h e i rf a m i l y
carers, delivered in their own homes, comprising
MDT assessment, care planning and treatment (fol-
l o w i n gt h ep r o t o c o lp r e v i o u s l ye v a l u a t e di nad a y
hospital setting);
2. Provide ongoing support from specially trained
care assistants to half (randomly selected) of those
receiving the specialist rehabilitation;
3. Evaluate the clinical effectiveness of the specialist
rehabilitation service, and the value added by
ongoing support from trained care assistants
embedded in the MDT, compared to usual care,
(which is largely non specialist and non team based),
across a range of patient and carer outcomes;
4. Assess the costs of the specialist rehabilitation
intervention, and of the ongoing care assistant sup-
port, and calculate relative cost-effectiveness, includ-
ing consideration of savings from service use offsets;
5. Investigate the acceptability of the new service
delivery models (specialist domiciliary rehabilitation
with and without ongoing support from trained care
assistants) from the perspectives of all stakeholders
including commissioners, MDT members, care assis-
tants, service managers, patients and family carers;
6. Deliver guidance for commissioners, providers and
policy makers about the acceptability, clinical and
cost-effectiveness of different models of specialist
neurological rehabilitation.
The hypotheses are that:
1. A package of domiciliary multidisciplinary specia-
list rehabilitation will benefit:
a. People with Parkinson’s in terms of maintain-
ing mobility and independence (primary outcome
for patients), and improving wellbeing and
health-related quality of life,
b. Family carers in terms of reduced strain (pri-
mary outcome for carers), and improved health-
related quality of life, and
c. Society through reduced use of other health
and social care services, including hospitalisa-
tions and admissions to long term care.
2. The addition of four months of ongoing support
from trained care assistants will help to maintain the
benefits of the specialist team rehabilitation, and
avoid the fading of effects that typically accompanies
the withdrawal of input.
3. The intervention will be acceptable to major sta-
keholders, and that barriers and facilitators to wider
implementation will be identified.
Design/Methods
Design
A pragmatic three parallel group randomised controlled
trial. People with Parkinson’s in group A will be assessed
and managed by a specialist MDT according to a care
plan that is agreed amongst the professionals and with
the patient and carer. Group B will additionally receive
ongoing support for four months from a trained care
assistant. Group C will receive normal care (no coordi-
nated MDT care planning or ongoing support). Follow
up will be for six months to determine the impact and
relative cost-effectiveness of the two interventions. Quali-
tative interviews will be undertaken with providers (MDT
members, care assistants), service commissioners, and
patients and carers in groups A and B, to gain feedback
about the acceptability of the interventions. The CON-
SORT diagram [42] summarises the design (Figure 1).
Setting
Contiguous communities around three district general
hospitals (DGHs) in the county of Surrey, England. The
study area contains urban, suburban and rural localities,
and a broad mix of socio-economic and ethnic groups.
Gage et al. Trials 2011, 12:250
http://www.trialsjournal.com/content/12/1/250
Page 3 of 12Participants
People with Parkinson’s (all stages of the disease) and
live-in carers (where applicable).
Recruitment
People with Parkinson’s disease will be identified by a vari-
ety of means including: hospital clinics; general
practitioners (GPs); Parkinson’sU Kc o n t a c t s ;P N S ,c o m -
munity-based therapists; word of mouth. Research nurses
from the Primary Care Research Network (PCRN) and the
Dementia’s and Neurodegenerative Diseases Research
Network (DeNDRoN) will assist with the identification of
people with Parkinson’s through general practices and spe-
cialist Parkinson’s hospital clinics respectively. Any
Assessment – 36 weeks  Assessment – 36 weeks  Assessment – 36 weeks 
Assessment – 24 weeks  Assessment – 24 weeks  Assessment – 24 weeks 
Care assistant support for 
4 months 
Assessment – 6 weeks  Assessment – 6 weeks  Assessment – 6 weeks 
Allocated to Group A           
n = 90 People with PD        
n = 71 Family carers            
6 weeks specialist 
rehabilitation 
Allocated to Group B            
n = 90 People with PD        
n = 71 Family carers            
6 weeks specialist 
rehabilitation and care 
assistant support 
Allocated to Group            
n = 90 People with PD        
n = 71 Family carers            
Usual care controls, given 
information pack 
Randomisation: n = 270 People with Parkinson’s; n = 213 Family carers 
Research nurse makes home visit to collect consent and baseline information from people with 
Parkinson’s and family carers. 
Community dwelling people with Parkinson’s Disease identified by hospital doctors, GPs, specialist 
nurses, Parkinson’s UK contacts, word of mouth, and given information about study.  Separate 
information for family carers.  Patients and carers opt into study. 
Figure 1 CONSORT Flow Chart for SPIRiTT (Specialist Parkinson’s Rehabilitation Team Trial).
Gage et al. Trials 2011, 12:250
http://www.trialsjournal.com/content/12/1/250
Page 4 of 12interested person with Parkinson’s will be given an infor-
mation leaflet. Separate information will be provided for
live-in carers (family, friends, paid carers living in the
same household), where appropriate. People with Parkin-
son’s and live-in carers will volunteer separately to take
part in the study by contacting the research team, who
will undertake an initial eligibility screen. This screening
will include asking the patient to confirm that a doctor
has told them that they have Parkinson’s disease. Volun-
teers who meet the inclusion criteria (see below) will be
sent full information about the trial, and a consent form,
and an appointment will be made for a research nurse to
make a home visit to collect baseline information. If a live-
in carer does not want to take part in the research, the
person with Parkinson’s may still join the trial. However,
carers will not be accepted if the person with Parkinson’s
does not want to participate.
Inclusion criteria
People with Parkinson’s (any stage of the disease) will be
included if they: are 18 years of age or over; have a clini-
cal diagnosis of Parkinson’s disease; are living in the
community (own home or minimally sheltered accom-
modation) with their own living areas; live in the county
of Surrey (for reasons associated with the funding of the
intervention); are able to read and write English in order
to complete the self report questionnaires; express a
commitment to participate over the duration of the
study and provide written consent.
Live-in carers will be included if they: are 18 years of
age, or over; are able to read and write English in order
to complete the self report questionnaires; express a
commitment to participate over the duration of the
study and provide written consent.
Consent and baseline data collection
Volunteers will be entered into the trial in blocks of thirty
(geographically defined in order to reduce travel time and
costs to participants’ homes for the collection of the
research data and delivery of the intervention). Research
nurses will make a home visit to collect written consent(s)
and record background information (age, gender, time
since diagnosis, disease stage, co-morbidities, housing, car-
ing arrangements, income and benefits, social support -
Lubben Social Network Scale [43], cognitive function -
mini mental state examination [44]). A baseline assess-
ment will also be conducted using the outcome measures
selected for the trial (see Table below). The intervention
for each block of participants will start within two weeks
of completion of baseline data collection.
Exclusion criteria
Exclusion criteria will be checked by the research nurse
at the baseline assessment. People with Parkinson’sw i l l
be excluded if they: score at the most favourable end of
all outcome scales at baseline, because the trial cannot
demonstrate an improvement in these patients, and, in
six months, has little likelihood of demonstrating reduc-
tion in any expected decline; score less than 24 on the
mini mental state examination at baseline assessment
[44], to ensure those recruited can follow instructions
associated with the rehabilitation intervention; are
already having a multidisciplinary package of care, or
have had such care in the last six months; are taking
part in another rehabilitation-based research study, or
have taken part in such research in the last six months.
Registration and randomisation
After consent and baseline data have been collected, eli-
gible volunteers will be given a unique registration num-
ber by the project administrator and randomised to
either: Group A - specialist rehabilitation, Group B -
specialist rehabilitation and ongoing care assistant sup-
port, or Group C - usual care, control group. A separate
randomisation sequence will be prepared by the study
statistician prior to the commencement of the study for
patients without live-in carers and for patients with live-
in carers. In each instance, blocked randomisation will
be used to formulate the sequence involving the three
comparison groups. A non-computerised random num-
ber generator will create random permuted blocks of
size three with an equal allocation ratio (with any of the
six different group sequences being equally possible).
The project administrator will inform: all participants of
the group to which they have been randomised; the
MDT of participants randomised to either of the treat-
ment arms; the GPs of all participants about their invol-
vement in the trial and the group to which they have
been randomised. Since the project administrator will
n o tb ei n v o l v e di nt h ep r o c e s s of consenting volunteers
into the study, and randomisation of eligible participants
will be conducted in chronological order of study entry,
no attempt will be made to conceal from the project
administrator the next groupt ow h i c ht h en e x tp a t i e n t
would be allocated. However, only the project adminis-
trator and the study statistician will have access to each
randomisation sequence.
Interventions
Specialist rehabilitation intervention (Groups A and B)
A multidisciplinary team comprising two each of PNS,
physiotherapist, occupational therapist, and speech and
language therapist will be ass e m b l e df r o ml o c a lp r o f e s -
sionals. They will work one day per week for the trial,
and in other duties for the rest of the time. Team mem-
bers will visit the homes of participants to deliver a spe-
cialist rehabilitation package, tailored to individual
needs. In order to make the outcome from the trial
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hospital [10-12], a similar programme of specialist reha-
bilitation will be provided comprising an initial assess-
ment, and the formation of an agreed care plan
reflecting the needs, wishes and expectations of the per-
son with Parkinson’s and carers. A group education
component in the day hospital trial cannot be replicated
in the domiciliary setting. As a substitute, the MDT will
provide participants with a folder containing 13 fact
sheets produced by Parkinson’sU Ka n dt h er e s e a r c h
team, covering various aspects of living with Parkinson’s
including: medications, physiotherapy exercises, foot
care, diet and nutrition, speech and language, relaxation
techniques, sleep and fatigue, continence and bowel
care, rights and benefits and advice for carers.
The rehabilitation intervention will be coordinated by
the PNS, and will involve specialist input from each pro-
fessional, over a period of six weeks. The team will meet
face-to-face four times in each six week cycle to discuss
patient plans and progress, and communicate by email
and telephone at other times. Two hospital consultants
(neurologist and geriatrician), both with a special inter-
est in movement disorders, can be called upon by the
MDT for medication changes or advice. Referrals to a
range of other professionals will be made as required,
including community psychologist, social care manager,
continence adviser, dietician and pharmacist. Overall
three days of professional time (including travel and
meeting time) is allowed for each person with Parkin-
son’s in the trial, but some people may need more and
others less than this. This input is largely equivalent to
the 9-12 hours of individualised nursing and therapy
input, and flexible access to other professionals, in the
previous day hospital trial.
Ongoing support (Group B)
In addition to the programme of specialist MDT rehabi-
litation, participants randomised to Group B will receive
ongoing support for four months from a care assistant
trained in Parkinson’s, starting at the end of the six
week MDT intervention. The care assistants will be part
of the MDT and will work under the supervision of the
PNS. About one hour per week per patient is allowed
for ongoing support, and contact will to be through a
mix of home visits and telephone, through which the
care assistant will monitor progress in implementation
of the agreed care plan and report back to the MDT. If
required, MDT members may continue to provide
input. Care assistants will be recruited to the project
from local health and social care employers and trained
using the material developed by the research team [45],
and through shadowing MDT members.
Usual Care/Control (Group C)
Participants in the control group will continue to receive
care as usual (no coordinated MDT care planning or
ongoing support). When informed of their group alloca-
tion, they will be sent locally relevant and generic infor-
mation about Parkinson’sd i s e a s e .T h i si sas m a l l
enhancement on the service they are likely to be receiv-
ing. In order to measure the impact of the interventions,
this information will also be given to the participants in
Groups A and B. At the end of the trial, people in the
control group will be offered an assessment by the
MDT, with advice, and the fact sheets provided to
groups A and B, but additional services cannot be
guaranteed.
Cross contamination between groups will be minimal
because patients will be individually recruited to the
study, and receive treatments tailored to their specific
needs. Moreover, the intervention and research assess-
ments will take place in participants’ homes which will
be geographically dispersed over the catchment areas of
three large district general hospitals.
Outcome measures
Participants in all groups will be assessed in their homes
by a research nurse, according to the schedule used in
the day hospital trial, at weeks 6 (after the rehabilitation
intervention), 24 (four months after the end rehabilita-
tion, coinciding with the end ongoing support for
Group B), and 36 (for final follow up). Validated instru-
ments which reflect the needs of participants (e.g. func-
tional outcomes, quality of life) and service
commissioners (e.g. service use), and which have been
found sensitive in previous rehabilitation studies under-
taken by the research team [10-13] have been selected
to measure outcomes (Table 1).
The instrument battery was developed and piloted in
collaboration with patient and carer representatives. It
takes about one hour to complete, and was not been
found too onerous. Research nurses will assist patients
with completion of questionnaires. Carers will be asked
to self complete the questionnaires that apply to them.
All questionnaires will be checked for completeness
before the research nurse leaves the participant’sh o m e .
Data will be entered by the research nurse shortly after
collection, and any queries referred back to the partici-
pant by telephone. A further check on data (complete-
ness and entry) will be undertaken by the research
manager when forms are returned to the office by the
research nurse, and missing items or other issues will be
resolved. Patient and carer outcomes will be analysed
separately.
Blinding
The research administrator will not disclose group allo-
cation to the research nurses who undertake assess-
ments, and participants will be asked not to discuss
aspects of the trial and treatments with them. However,
Gage et al. Trials 2011, 12:250
http://www.trialsjournal.com/content/12/1/250
Page 6 of 12it is recognised that blinding of the research nurses may
be compromised in trials of this nature. As a check on
blinding, research nurses will be asked to guess partici-
pants’ groups at the end of the trial. For data analysis,
the group identifiers will not be disclosed to the
statistician.
Acceptability of the intervention
Semi structured interview schedules will be designed
and used to gather feedback on the acceptability of the
interventions from group A and B participants during
the 24 week research assessment. This part of the study
will capture the patient and carer voice and experience
of the rehabilitation interventions relative to perceived
needs and priorities. In addition, service providers,
MDT members, care assistants and a selection of com-
missioners will be asked for their views about the inter-
ventions, to identify strengths and weaknesses, barriers
and facilitators to the wider use of the interventions.
Sample size calculations
Patient sample size calculations were based on detecting
clinically meaningful differences in the primary patient
outcome measure. Carer sample sizes reflect the
findings of our previous work that suggest that 79% of
people with Parkinson’s have a carer [10].
We will recruit 270 people with Parkinson’so v e ra1 2
month period across the three areas, 90 of whom will
be randomly allocated to each of the three groups. This
calculation is based on the numbers of people with Par-
kinson’s needed to detect differences between groups in
patient primary outcome measure score.
Assuming a similar level of variation in Self Assess-
ment Parkinson’s Disease Disability Scale [46] to the day
hospital trial [11], in order to detect a difference in the
disability score of 1.25 (assuming SD = 2.5, size = 5%,
power = 80% and a 2 sided test), 64 subjects with Par-
kinson’s disease are needed in each of the three groups.
Assuming a similar level of variation in Carer Strain
Index [56] to the day hospital trial [11], in order to
d e t e c tad i f f e r e n c ei nt h eC a r e rS t r a i nI n d e xo f0 . 5 3 5
(assuming SD = 1.07, size = 5%, power = 80% and a 2
sided test), 64 carers are needed in each of the three
groups. In the previous study, 79% of community dwell-
ing people with Parkinson’s had a live-in carer [10].
Thus, if we have 64 carers per group, this will necessi-
tate 246 [(64*3)/0.79 = 243.04] Parkinson’ss u b j e c t s ,i . e
82 per group.
Table 1 Trial outcome measures and instruments: baseline, 6, 24 and 36 weeks
Participant Outcome measure Instrument
Person with
Parkinson’s
Parkinson’s disability/general activities Self Assessment Parkinson’s Disease Disability Scale [46] (PRIMARY OUTCOME)
Parkinson’s specific Parkinson’s Disease Questionnaire [47]
Non Motor Symptom Questionnaire [48]
Mobility Posture and gait items from the Unified Parkinson’s Disease Rating Scale [49]
Timed up and go [50]
Falls Self report
Speech Single speech item from the Unified Parkinson’s Disease Rating Scale [49]
Abridged Emerson and Enderby Screening Assessment Rating Scale [51]
Frenchay Dysarthria Summary [52]
Speech self report questionnaire [10-12]
Pain Visual analogue scale [53]
Generic health related quality of life/
QALYs
Euro Qol 5D, with utility index for calculation of quality adjusted life years (QALYs)
[54]
Self efficacy Self efficacy scale [55]
Health and social care utilisation Customised proforma and patient records
Live-in carer Carer strain Modified caregiver strain index [56]
(PRIMARY OUTCOME)
General health General health questionnaire - 12 [57]
Both Activities of daily living Barthel ADL index [58]
Social activities Frenchay Activities index [59]
Psychological wellbeing Hospital Anxiety and Depression Scale [60]
Yale single item depression screening tool [61]
Generic health related quality of life Short form - 36 Health Survey [62]
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non completion/missing data rate between recruitment
and six month assessments was 26%. However, in this
trial, participants attended the day hospital for treatment
(six visits) and research assessments (four visits), and
difficulties with transport and inter-current illness
accounted for missing data and drop-out. We expect
less attrition in the SPIRiTT trial because participants
will receive both treatment and the research assessments
in their own homes, at times convenient to them.
If we allow for 10% loss to follow up/non completion/
missing data rates for people with Parkinson’s, then
243.04/.90 = 270.03 patients are required = 90 per
group. With 90 patients per group, we expect to recruit
71 carers per group. These group sizes will also ensure
that the samples for patients and carers will both remain
above the critical values of 64 if there were a loss of 5%
of carers (and associated patients) and an independent
loss of 5% of people with Parkinson’s. Intention to treat
analysis will be used.
Withdrawals
Participants may withdraw from the study due to illness
or personal reasons. They will be made aware (via the
information sheet and consent form) that withdrawal
from the study will not affect their future care, and that
data collected to date will still be used in the final analy-
sis. Volunteers who are not randomised because they fail
eligibility criteria at baseline will be replaced, but partici-
pants who withdraw from the trial for any reason will
not be replaced.
Statistical methods
Data will be entered into an SPSS (latest version) com-
puter data-base using the registration number to identify
the participant. All paper data will be stored in a secure
locked cabinet, and all computer data will be stored on
a secure server.
Baseline data will be analysed to describe the charac-
teristics of the participants and to check for significant
imbalance between the three groups. All outcomes will
be analysed at each follow up assessment point (six, 24
and 36 weeks), and specific ap r i o r ihypotheses will be
tested reflecting the outcomes that we expect to identify
at the different stages. In each case a two sided test will
b eu s e d .I ti se x p e c t e dt h a ttt e s t sw i l lb ec o n d u c t e dt o
compare groups, unless any obvious deviations from t
test assumptions are found in the outcomes, in which
case the non - parametric Mann Whitney U test will be
used.
In order to identify short term benefits, participants in
the specialist rehabilitation groups (A and B) will be
compared with participants receiving information pack
only (group C) at six weeks. The null hypotheses will be
tested, that there are no differences between the groups,
with respect to change in patient disability, mobility and
psychological wellbeing, and in carer strain. These
hypotheses will be tested using each participant’s change
score from baseline (week 0) to week 6.
In order to identify medium term benefits, compari-
sons will be made at 24 weeks between pairs of treat-
ment groups (Group A vs. Group B; Group A vs. Group
C; Group B vs. Group C). The null hypotheses will be
tested, that there are no differences between the groups
with respect to change in patient disability, mobility,
falls, speech, activities of daily living, social activities,
psychological wellbeing, health related quality of life and
use of health and social care services, and in carer
strain, social activities and health related quality of life.
These hypotheses will be tested using each participant’s
change score from baseline (week 0) to week 24.
In order to show loss or maintenance of benefit
resulting from specialist rehabilitation, Group A (no
ongoing support weeks 7 and 24) will be compared with
Group B (ongoing support weeks 7 to 24) using the
hypotheses in the medium term analysis and each parti-
cipant’s change score from week 6 to week 24.
In order to identify longer term benefits, comparisons
will be made at 36 weeks between pairs of treatment
groups (Group A vs. Group B; Group A vs. Group C;
G r o u pBv s .G r o u pC ) .T h en u l lh y p o t h e s e sw i l lb e
tested, that there are no differences between the groups
with respect to change in patient disability, mobility,
falls, speech, activities of daily living, social activities,
psychological wellbeing, health related quality of life and
use of health and social care services, and in carer
strain, social activities and health related quality of life.
These hypotheses will be tested using each participant’s
change score from baseline (week 0) to week 36.
An additional exploratory analysis will be performed
using each participants change score for the above out-
comes between week 24 and week 36. This is the fol-
low-up period, and this analysis will provide evidence of
trends in each group, and difference between groups,
after all interventions cease in week 24.
It is recognised that multiple statistical tests are being
undertaken, but no adjustments will be needed for mul-
tiple testing because a priori hypotheses have been sti-
pulated, and the selective reporting of significant results
will be avoided. Any additional exploratory (hypothesis
generating) data analyses will make allowance for multi-
ple testing in the usual way (Bonferroni).
Missing data
Stringent attempts will be made to minimise missing
data through checking of questionnaires as they are
completed, and returning to participants to retrieve
missing items. Participants with missing outcome data
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that stage. Multiple imputation will be used to estimate
missing outcome scores in repeated measures analysis.
Economic evaluation
The resources used in the delivery of the interventions
will be collected at the patient level from records kept
by the MDT (Groups A and B), and the care assistants
(Group B only). These data will include details of
patient contact (number and duration of visits or tele-
phone calls), travel time and distance for home visits,
materials, consumables or equipment used, time spent
liaising with other professionals (e.g. consultant, GP),
and referrals made. Administrative and meeting time of
the MDT will be averaged across participants in recruit-
ment blocks of thirty. Monetary costs will be assigned
to all resources used to ascertain a cost for each partici-
pant, and group means and variation calculated and
compared. Unit costs of resources will be based on data
from local financial managers, validated national sources
[63], and market prices, as appropriate, and multiplied
by the number of units used.
The use of health and social care services (GP, com-
munity, outpatient, A&E, hospital inpatient) will be col-
lected by self report at each assessment point by recall
for the previous period (three months prior to baseline).
Responses will be verified as far as possible (within the
resources of the trial) from local records. Unit costs of
services will be obtained from local and national sources
[63] and multiplied by the number of units used. Costs
of service utilisation in the intervention groups (A and
B) will be compared with each other and with the usual
care group (C) to assess the extent to which the inter-
v e n t i o n sm a yb eo f f s e tb ys a v i n g se l s e w h e r ei nt h e
health and social care system.
The economic analysis will evaluate the costs of the
intervention in relation to all patient and carer conse-
quences/outcomes [64]. In addition, a cost-effectiveness
analysis will be conducted, using standard techniques of
economic appraisal [65]. Mean differences between
groups (Group A (specialist rehabilitation only) vs.
group C (normal care controls); Group B (rehabilitation
with ongoing support) vs. Group A) in the primary out-
come measures (disability score for patients, carer
strain) and in QALYs (patients only) adjusted for base-
line values in an analysis of covariance, will be used to
measure effectiveness. If statistically significant differ-
ences between groups are found, incremental cost-effec-
tiveness ratios will be calculated to show the extra cost
incurred per unit of therapeutic gain/QALY gain. Sec-
ondary cost-effectiveness analyses will be conducted
using other outcomes as measures of effectiveness.
The impact of uncertainties in the estimation of costs
and outcome variables will be explored using one way
and probabilistic sensitivity analysis. Bootstrap methods
will be used to represent uncertainty of estimates, either
for constructing confidence intervals or probability
curves. Sensitivity analysis will also investigate the cost-
effectiveness of the interventions for people with differ-
ent levels of disability at baseline.
Risks and adverse events
An adverse event (AE) is any unfavourable or unin-
tended sign, symptom, syndrome or illness that develops
or worsens during the period of the trial. A serious
adverse event (SAE) is any adverse event which is life
threatening, or results in hospitalisation, disability or
death. AE and SAE will be identified by research or
intervention team members, or reported by participants.
They will be recorded, assessed for seriousness, expect-
edness and causality by clinical members of the research
team and monitored. Any SAE deemed to be directly
related to, or suspected to be related to the intervention
and unexpected will be reported to the study Steering
Group and the Ethics Committee.
Risks to participants from the trial are considered
small, and no higher than those of usual care. The
aspects of the MDT intervention delivered by the indivi-
dual therapists are standard practice and aim to improve
self awareness and management. Home visits will
include assessment of home safety and aids and adapta-
tions required which may require in improvements in
safety for participants. However, it is possible that
encouragement to exercise more could result in falls
that might not otherwise have occurred. The MDT
members experienced professionals and will emphasise
safety issues to participants. The care assistants will be
fully trained, and will work under the instruction of
team professionals, in the support of patients and carers
and the implementation of the agreed care plan. Other
potential harms to the experimental groups include
depression if raised expectations are not met, distress
when additional input is stopped, and loss of support
from family and friends if the additional care is per-
ceived to reduce the need for informal support.
Management and governance
The research team comprises a chief investigator (HG)
with overall responsibility for the conduct of the
research, two clinical principal investigators (BC, PT), a
full time research manager (ST), a qualitative researcher
(KB), a statistician (PW), research advisor (DW), and a
co-ordinator of public and patient involvement (JK). All
aspects of data collection and management are under
the supervision of the research manager. The research
team is supported in the delivery of the trial by an
External Steering Committee, which meets twice per
year to review progress and ensure timely completion of
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Page 9 of 12milestones. Membership of the EAG includes clinical
experts, experienced researchers, a statistician, represen-
tatives from Parkinson’s UK and the European Parkin-
son’s Disease Association, local service providers and
commissioners, and people with Parkinson’s and carers.
A separate PPI (Patient and Public Involvement) group,
co-ordinated by a Parkinson’s Specialist Nurse, helps the
research team with the development of study documents
and processes, and was involved in the planning stage of
the project.
Ethical and organisational review
Ethical approval has been granted to the Surrey
Research Ethics Committee (application number 10/
H1109/1). National Health Service Research and Devel-
opment approval has been granted by four Participant
Identification Centres.
Discussion
The SPIRiTT trial is a community based MDT rehabili-
tation intervention for people with Parkinson’sd i s e a s e
and their live-in carers. The intervention is delivered to
people in their own homes, so that the costs and effec-
tiveness can be compared with a similar intervention
delivered to the same patient group in a day hospital
setting. Findings will be compared with another commu-
nity-based RCT, conducted in England recently that
found no significant difference in outcomes or costs of
patients receiving rehabilitation in a day hospital rather
than in their own homes [66].
We anticipate several problems in the conduct of the
trial and will put processes in place to avert or minimise
their effect. First, retention of participants, particularly
in the control group, may be difficult so we will seek to
retain their interest by providing regular newsletters
reporting trial progress. Patients randomised to the con-
trol group will be offered an MDT assessment and
advice on completion of the trial follow up. Second, dis-
ruptions to the delivery of the MDT intervention may
arise due to bad weather preventing travel, or staff sick-
ness. We expect such interruptions will be minimal and
consistent with a pragmatic approach to research on
service delivery, and that cover will be available within
the team for short term holiday or sickness leave. Third,
lack of local NHS resources, due to financial exigencies,
could impede the delivery of the intervention according
to protocol to the numbers of patients and carers
required by the sample size calculations, but we will
liaise with local commissioners and providers to try and
ensure their support. Fourth, recruiting MDT members
and care assistants may be problematical, due to difficul-
ties arranging temporary secondments from local provi-
ders, and local labour market conditions. We will
address any staffing issues by advertising widely and
offering favourable contracts for suitably qualified appli-
cants. Lastly we may encounter difficulties in persuading
live-in carers to take part in the research assessments,
and we will seek to overcome this by explaining why
their participation is important to the findings.
The trial investigates important issues in recent
national policy recommendations for people with long
term conditions, and Parkinson’s disease in particular,
and will provide guidance to inform local service plan-
ning and commissioning. The population of the study
a r e ai sd i v e r s ea n df i n d i n g sa r em o r ew i d e l y
generalisable.
Trial status
Ongoing
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